Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN

NCT01054625 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT01054625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01054625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2010
Completion date
October 31, 2011
Enrollment
31 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer